Guggenheim Capital LLC Biomarin Pharmaceutical Inc Transaction History

Guggenheim Capital LLC

  • $14 Billion
  • Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 39,955 shares of BMRN stock, worth $2.66 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
39,955
Previous 41,322 3.31%
Holding current value
$2.66 Million
Previous $3.4 Million 17.46%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$69.02 - $93.84 $94,350 - $128,279
-1,367 Reduced 3.31%
39,955 $2.81 Million
Q2 2024

Aug 14, 2024
SELL
$74.43 - $92.22 $352,053 - $436,200
-4,730 Reduced 10.27%
41,322 $3.4 Million
Q1 2024

May 14, 2024
BUY
$83.81 - $99.0 $376,055 - $444,213
4,487 Added 10.8%
46,052 $4.02 Million
Q4 2023

Feb 14, 2024
SELL
$76.22 - $98.51 $281,251 - $363,501
-3,690 Reduced 8.15%
41,565 $4.01 Million
Q3 2023

Nov 14, 2023
SELL
$85.07 - $94.48 $370,054 - $410,988
-4,350 Reduced 8.77%
45,255 $4 Million
Q2 2023

Aug 11, 2023
BUY
$86.68 - $100.3 $581,102 - $672,411
6,704 Added 15.63%
49,605 $4.3 Million
Q1 2023

May 10, 2023
SELL
$87.74 - $117.27 $439,050 - $586,819
-5,004 Reduced 10.45%
42,901 $4.17 Million
Q4 2022

Feb 14, 2023
BUY
$80.93 - $108.63 $163,802 - $219,867
2,024 Added 4.41%
47,905 $4.96 Million
Q3 2022

Nov 14, 2022
SELL
$82.16 - $96.94 $828,747 - $977,833
-10,087 Reduced 18.02%
45,881 $3.89 Million
Q2 2022

Aug 15, 2022
SELL
$71.48 - $86.85 $205,719 - $249,954
-2,878 Reduced 4.89%
55,968 $4.64 Million
Q1 2022

May 16, 2022
SELL
$74.28 - $92.69 $531,919 - $663,753
-7,161 Reduced 10.85%
58,846 $4.54 Million
Q4 2021

Feb 14, 2022
BUY
$71.72 - $91.47 $154,054 - $196,477
2,148 Added 3.36%
66,007 $5.83 Million
Q3 2021

Nov 15, 2021
BUY
$74.77 - $85.47 $74,545 - $85,213
997 Added 1.59%
63,859 $4.94 Million
Q2 2021

Aug 13, 2021
SELL
$75.51 - $84.79 $160,911 - $180,687
-2,131 Reduced 3.28%
62,862 $5.25 Million
Q1 2021

May 13, 2021
BUY
$74.73 - $90.69 $240,331 - $291,659
3,216 Added 5.21%
64,993 $4.91 Million
Q4 2020

Feb 16, 2021
SELL
$72.61 - $90.2 $3.38 Million - $4.2 Million
-46,553 Reduced 42.97%
61,777 $5.42 Million
Q3 2020

Nov 13, 2020
SELL
$71.87 - $131.03 $330,961 - $603,393
-4,605 Reduced 4.08%
108,330 $8.24 Million
Q2 2020

Aug 14, 2020
BUY
$79.55 - $124.22 $669,651 - $1.05 Million
8,418 Added 8.05%
112,935 $13.9 Million
Q1 2020

Jun 02, 2020
SELL
$71.37 - $96.85 $1.39 Million - $1.88 Million
-19,436 Reduced 15.68%
104,517 $8.83 Million
Q4 2019

Feb 14, 2020
BUY
$64.27 - $86.37 $647,777 - $870,523
10,079 Added 8.85%
123,953 $10.5 Million
Q3 2019

Nov 14, 2019
SELL
$67.4 - $85.11 $148,010 - $186,901
-2,196 Reduced 1.89%
113,874 $7.68 Million
Q2 2019

Aug 14, 2019
SELL
$80.35 - $93.9 $503,473 - $588,377
-6,266 Reduced 5.12%
116,070 $9.94 Million
Q1 2019

May 15, 2019
BUY
$84.2 - $98.62 $468,994 - $549,313
5,570 Added 4.77%
122,336 $10.9 Million
Q4 2018

Feb 14, 2019
SELL
$80.14 - $106.07 $508,167 - $672,589
-6,341 Reduced 5.15%
116,766 $9.94 Million
Q3 2018

Nov 14, 2018
SELL
$93.92 - $105.72 $528,957 - $595,415
-5,632 Reduced 4.37%
123,107 $11.9 Million
Q2 2018

Aug 14, 2018
SELL
$76.01 - $99.03 $278,424 - $362,746
-3,663 Reduced 2.77%
128,739 $12.1 Million
Q1 2018

May 15, 2018
BUY
$77.67 - $92.63 $150,990 - $180,072
1,944 Added 1.49%
132,402 $10.7 Million
Q4 2017

Feb 14, 2018
SELL
$80.76 - $95.13 $1.43 Million - $1.68 Million
-17,699 Reduced 11.95%
130,458 $11.6 Million
Q3 2017

Nov 14, 2017
BUY
$80.6 - $94.95 $11.9 Million - $14.1 Million
148,157
148,157 $13.8 Million

Others Institutions Holding BMRN

# of Institutions
637
Shares Held
177M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email